Study Shows 1/2 of Early-Stage Breast Cancer Patients Can Safely Avoid Chemo When Using MammaPrint

 

If you have been diagnosed with early-stage breast cancer, talk to your doctor about The MammaPrint breast cancer test.  

 

According to the recently published RASTER Study, The MammaPrint breast cancer test (developed by Agendia) can accurately determine which early stage breast cancer patients are at low risk of breast cancer recurrence and can therefore safely choose not to undergo chemotherapy. Furthermore, the study suggests that half of early-stage breast cancer patients may be able to safely avoid chemotherapy.

 

Here’s the dealio (as my daughter always says)…

427 breast cancer patients were studied over 5 years. Of the 219 patients who were determined to be ‘low risk’ based on the MammaPrint test, 85% chose not to have chemotherapy. Of those patients, 97% were disease-free after 5 years. Of the 208 patients who were determined to be ‘high risk’, 81% chose chemotherapy and 91% were disease-free after 5 years.  This is the first breast cancer genomic study to include 5-year outcome data.

 

The MammaPrint test analyzes 70 critical genes identified in breast cancer metastasis (3x more genes than previous-generation testing); can be used on both hormone-receptor-positive or hormone-receptor-negative early stage breast cancers; and has been FDA-cleared in the US.

 

For more information, visit Agendia.com.  If you don’t have insurance or your insurance company doesn’t cover MammaPrint testing, contact the Agendia Cares Program as they may be able to help.  To compare MammaPrint against other genetic assay tests such as Oncotype DX or Mammostrat, speak with your doctor and visit BreastCancer.org.

 

(Sources:  Agendia PR ; BreastCancer.org, MedScape, European Cancer Organization)

2 comments

  1. Bill Williams says:

    Oncotype DX has 10 year outcome data and has 95% confidence intervals and includes level 1 evidence for prognosis and level 2A for chemo benefit. Mammaprint is not even in the game for Chemo prediction and is not included in the recognized guidelines. Oncotype Is in the NCCN nationally recognized guidelines Mammaprint is not.

    • Robyn says:

      Thanks so much for your comment Bill. Patients must speak with their doctors and ask lots of questions. The more informed patients are, the better choices they can make.

Leave a Reply

Your email address will not be published. Required fields are marked *